|
Storage
|
Store the unopened product at 2 - 8° C. Protect from light. Do not use past
expiration date.
|
|
Gene ID
|
3902 |
|
Gene Symbol
|
LAG-3 |
|
Synonym
|
CD223 antigen; CD223; FDC; LAG3; LAG-3; lymphocyte activation gene 3 protein; lymphocyte-activation gene 3; Protein FDC |
|
Species
|
Human |
|
Specificity
|
This assay has high sensitivity and excellent specificity for detection of human LAG-3. No significant cross-reactivity or interference between human LAG-3 and analogues was observed. |
|
Kit Components
|
Assay plate (12 x 8 coated Microwells), Standard (Freeze dried), Biotin-antibody (60 x concentrate), HRP-avidin (20 x concentrate), Biotin-antibody Diluent, HRP-avidin Diluent, Sample Diluent, Wash Buffer (20 x concentrate), TMB Substrate, Stop Solution, Adhesive Strip (For 96 wells), Instruction manual |
|
Notes
|
Please contact our Technical Services with any questions regarding species reactivity |
|
Standard Curve Range
|
93.8 pg/ml - 6000 pg/ml |
|
Sensitivity
|
75 pg/ml |
|
Inter Assay
|
CV%<10% |
|
Intra Assay
|
CV%<8% |
|
Assay Type
|
Sandwich ELISA |
|
Suitable Sample Type
|
serum, plasma, tissue homogenates, cell lysate, cell culture medium. |
|
Sample Volume
|
50-100ul |
|
Applications
|
ELISA |
|
Typical Data
|
ELISA: Human LAG-3 ELISA Kit (Colorimetric) - These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed. |
|
Background
|
Lymphocyte-activation gene 3, also known as LAG-3, is a protein which in humans is encoded by the LAG3 gene. LAG3, which was discovered in 1990 and was designated CD223 (cluster of differentiation 223) after the Seventh Human Leucocyte Differentiation Antigen Workshop in 2000, is a cell surface molecule with diverse biologic effects on T cell function. It is an immune checkpoint receptor and as such is the target of various drug development programs by pharmaceutical companies seeking to develop new treatments for cancer and autoimmune disorders. In soluble form it is also being developed as a cancer drug in its own right. LAG3's main ligand is MHC class II, to which it binds with higher affinity than CD4. The protein negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar fashion to CTLA-4 and PD-1 and has been reported to play a role in Treg suppressive function. LAG3 also helps maintain CD8+ T cells in a tolerogenic state[9] and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection. LAG3 is known to be involved in the maturation and activation of dendritic cells. |
